Executive Summary / Key Takeaways

• Becton, Dickinson and Company is executing a multi-year transformation under its BD 2025 strategy, focusing on portfolio optimization, operational efficiency, and targeted innovation to drive durable growth and value creation.
• Recent financial performance, particularly in Q2 FY25, reflects strong operational execution and margin expansion driven by the BD Excellence program, successfully offsetting some market-driven revenue softness in certain segments.
• The company is strategically positioning itself in high-growth areas like connected care, biologic drug delivery (including GLP-1s), advanced patient monitoring, and healthcare automation, leveraging differentiated technology and a robust innovation pipeline.
• BD faces near-term market headwinds, notably in China (volume-based procurement, research funding) and certain Life Sciences and Pharmaceutical Systems areas (research funding, destocking), alongside regulatory and litigation risks, which have led to a revised FY25 organic revenue growth outlook.
• The planned separation of the Biosciences and Diagnostic Solutions business is a significant strategic move aimed at enhancing focus and unlocking value for both the resulting MedTech and Life Science Tools & Diagnostics entities, targeted for completion in FY26.

The Evolving Landscape of a MedTech Giant

Becton, Dickinson and Company, a global medical technology leader, stands at a pivotal juncture, actively reshaping its portfolio and operational structure to navigate a dynamic healthcare landscape. The company's journey, marked by significant strategic acquisitions like CareFusion and C.R. Bard and targeted divestitures such as the Diabetes Care spin-off, has culminated in the BD 2025 strategy. This multi-year initiative is designed to transform BD into a faster-growing, more profitable entity by strategically shifting its focus towards higher-growth markets and embedding a culture of operational excellence.

The medical technology industry, while fundamentally driven by persistent healthcare needs, is subject to macro pressures including inflation, supply chain volatility, and evolving market dynamics in key geographies like China. Against this backdrop, BD operates across broad and attractive markets, maintaining leadership positions in critical areas such as medication delivery, pharmaceutical systems, and certain diagnostic and interventional spaces. The competitive environment includes larger diversified players as well as smaller, more agile niche competitors specializing in specific technologies or market segments. BD's scale, diversified portfolio, and established global distribution network provide a significant competitive advantage, enabling broader market penetration and resilience compared to smaller rivals who may struggle with scalability and market access. However, competition remains intense, with rivals constantly innovating and vying for market share through technology, pricing, and strategic alliances.

Central to BD's competitive strategy is its portfolio of differentiated technologies. In medication management, the Alaris Infusion System, now returning to market and gaining traction, is notable for being the only infusion system with an integrated EtCO2 module, enhancing patient safety by monitoring respiratory status and pausing the pump when necessary. The forthcoming next-generation Pyxis platform, set to integrate with a new AI platform, aims to leverage data from millions of BD's smart devices to improve outcomes and efficiencies. In diagnostics, the BD Onclarity HPV Assay stands out as the only test with extended genotyping FDA-approved for self-collection, offering a more precise and convenient screening method. The Biosciences segment boasts the BD FACSDiscover platform, featuring unique SpectralFX and CellView technologies that enabled the world's first 50-color flow cytometry experiment, pushing the boundaries of cell analysis. In vascular access, the BD PIVO Pro Needle-free Blood Collection Device offers tangible benefits by reducing needlesticks, pain, and injury risk while streamlining workflows. Within interventional surgery, the recently launched Phasix ST Umbilical Hernia Patch is the first fully absorbable patch designed specifically for umbilical hernia repair, leveraging established surgical techniques. These technological advancements, coupled with ongoing R&D initiatives like the AI incubator and development of wearable injectors (BD Libertas, BD Evolve) for next-generation biologics, underscore BD's commitment to innovation. The strategic intent behind these efforts is to create products that offer quantifiable benefits in terms of safety, efficiency, accuracy, and patient experience, thereby strengthening BD's market position and supporting premium pricing or cost advantages. The company's significant R&D investment, exceeding $1 billion annually, is directed towards advancing these platforms and exploring new opportunities in areas like healthcare automation and AI informatics, a business segment BD expects to grow substantially in the coming years.

Performance Amidst Transition

BD's recent financial performance reflects the interplay of strategic execution and external pressures. For the three months ended March 31, 2025, BD reported total revenues of $5.27 billion, a 4.5% increase from the prior-year period (6.0% currency-neutral, but only 0.9% organic). This organic growth fell below expectations, primarily attributed to market dynamics within the Life Sciences segment, specifically changes in research funding policy and a slower-than-anticipated recovery in the BACTEC blood culture business.

Segment performance in Q2 FY25 showed varied results. The Medical segment saw strong revenue growth (12.7% reported, 14.3% FXN), driven by volume growth in Medication Delivery Solutions, double-digit growth in Medication Management Solutions (infusion systems), and contributions from the newly acquired Advanced Patient Monitoring (APM) unit. Pharmaceutical Systems also returned to growth, fueled by demand for biologic drug delivery solutions, including GLP-1s. The Life Sciences segment experienced a revenue decline (4.3% reported, 2.4% FXN), impacted by the aforementioned challenges in Diagnostic Solutions and Biosciences, where lower instrument demand globally, particularly in government and academic sectors affected by research funding levels, offset growth in Specimen Management and reagents. The Interventional segment also saw a slight revenue decrease (2.2% reported, 1.1% FXN), influenced by an unfavorable comparison to prior-period licensing revenue, despite strong performance in Surgery (Phasix, biosurgery) and continued double-digit growth in PureWick offerings.

\

Profitability metrics highlight the impact of operational efficiency initiatives. Adjusted gross margin in Q2 FY25 reached 54.9%, a significant 190 basis point increase year-over-year, and adjusted operating margin was 24.9%, up 60 basis points. This margin expansion is largely attributed to the momentum of the BD Excellence operating system, which is driving manufacturing productivity, improving operating equipment efficiency (OEE), reducing waste, and optimizing the supply chain. While gross margins benefited, operating income percentage in the Medical segment declined due to specific charges related to the APM acquisition (fair value step-up on inventory, intangible amortization) and product remediation costs, as well as higher selling and administrative expenses associated with APM. Life Sciences operating margin also saw a slight decrease, impacted by higher SG&A and R&D spending.

Cash flow generation remains a focus. Year-to-date FY25 free cash flow was approximately $625 million, influenced by the timing of planned one-time cash payments. The company continues to leverage capital expenditures through BD Excellence productivity gains and made strategic inventory investments in Q2 to mitigate potential tariff impacts. BD ended Q2 FY25 with net leverage of 2.9x, in line with expectations, and remains committed to its deleveraging targets and returning capital to shareholders, including a plan to deploy $1 billion for share repurchases by the end of the calendar year.

Outlook and Strategic Evolution

Looking ahead, BD has adjusted its full-year fiscal 2025 guidance to reflect the persistent market dynamics observed in the first half. The company now expects organic revenue growth of 3% to 3.5% (down from the initial 4% to 4.5% forecast). Total revenues are projected to be in the range of $21.8 billion to $21.9 billion. This revised outlook incorporates an estimated $90 million impact from tariffs to FY25 operating expense, predominantly weighted to Q4, primarily related to China and imports.

Despite the lowered revenue growth forecast, BD maintains confidence in its ability to deliver compelling adjusted EPS growth, projecting a range of $14.06 to $14.34, reflecting growth of about 8% at the midpoint. This is supported by the strength of the P&L, where margin improvements driven by BD Excellence are expected to largely offset the earnings impact of the revised organic sales growth before accounting for tariffs. The estimated $0.25 tariff impact is the primary driver of the reduction from the prior EPS guidance range of $14.30 to $14.60.

Management anticipates a sequential improvement in organic growth in the second half of FY25, with Q3 expected to be near 3% and Q4 projected to exceed 5%. This acceleration is expected to be driven by several factors: the anniversary of the APM acquisition (which will then contribute to organic growth), continued momentum in Pharmaceutical Systems (particularly biologics and GLP-1 orders), strength in the Interventional segment (PureWick, Phasix), and the launch of new products like the FACSDiscover A8 in Biosciences, alongside easier prior-year comparisons.

A significant strategic development shaping BD's future is the announced intention to separate its Biosciences and Diagnostic Solutions business. This move, targeted for completion in fiscal year 2026, is intended to create two more focused entities: a pure-play MedTech company ("New BD") and a pure-play Life Science Tools & Diagnostics leader. This separation is viewed as a natural progression of the BD 2025 strategy, designed to enhance strategic focus, enable more targeted capital deployment in R&D and M&A within each entity's specific market, and ultimately unlock significant value for shareholders. The company is exploring various transaction forms, including spin-off, sale, or Reverse Morris Trust, with the goal of maximizing shareholder value.

Risks and Considerations

While BD's strategic direction and operational execution demonstrate resilience, investors must consider several key risks. Market dynamics in China, including the ongoing impact of volume-based procurement and reduced research funding, present a persistent challenge to revenue growth in that important region. Fluctuations in global governmental research funding also directly impact the Biosciences segment. Regulatory risks remain significant, particularly concerning the Alaris infusion pump business operating under a Consent Decree and the recent Warning Letter related to the Dispensing quality management system, which could lead to regulatory actions or financial penalties. Litigation risks, including product liability claims (hernia repair, pelvic mesh, IVC filters, implantable ports) and environmental matters (EtO sterilization), could result in substantial charges. The increasing regulatory focus on EtO sterilization could also disrupt manufacturing or supply chains. Furthermore, the successful execution of the planned separation of the Biosciences and Diagnostic Solutions business is subject to various conditions and approvals, and there is no assurance regarding the specific terms, timing, or whether the separation will ultimately occur. Tariffs and other trade barriers also pose a financial risk, as highlighted by the estimated impact on FY25 operating expense.

Conclusion

Becton, Dickinson and Company is actively transforming its business through strategic portfolio management, operational excellence, and targeted innovation. The BD 2025 strategy has laid a foundation for shifting towards higher-growth markets and improving profitability, evidenced by recent margin expansion driven by the BD Excellence program. While facing near-term market headwinds in key areas like China and parts of Life Sciences and Pharmaceutical Systems, the company's diversified portfolio, leadership positions, and pipeline of differentiated technologies in areas like connected care, biologic drug delivery, and automation position it for long-term growth. The planned separation of the Biosciences and Diagnostic Solutions business represents a bold step to further sharpen strategic focus and unlock value. Investors should monitor the execution of the BD Excellence initiatives, the progress of the planned separation, the recovery trajectory of impacted markets, and the management of regulatory and litigation risks as key indicators of the company's ability to deliver on its value creation objectives amidst a complex operating environment.